BioASP portal provides Dutch researchers access to Rosetta Resolver software in National Genomics Initiative
Stichting Netherlands bioinformatics Centre, Rosetta Biosoftware and Agilent Technologies Inc. today announced an agreement to make the Rosetta Resolver(r) system available to the Dutch research community. The Stichting NBIC has obtained a license to the Rosetta Resolver system in which access will be made available through NBIC's BioASP portal to a larger group of Dutch researchers. BioASP maintains a unique Application Service Provider (ASP) model for a wide group of researchers in the Netherlands and will provide the required infrastructure, support and expertise to users in at least 10 academic research labs, with this number expected to grow.
The Rosetta Resolver system is an enterprise-wide gene expression data analysis system that is developed by Rosetta Biosoftware and distributed exclusively by Agilent, a leading gene expression solutions provider. Researchers use gene expression technologies to measure cellular gene activity under different conditions with the goal of understanding the molecular basis of disease and discovering new treatments. High-quality analytical software is critical for the interpretation of gene expression data.
Cooperation in Dutch Research
The BioASP (Bioinformatics Applications Service Provider) portal is an integral part of the strategy outlined by the National Genomics Initiative, a cabinet-appointed task force established in the Netherlands in late 2001. By combining the opportunities offered by genomics research with the scientific knowledge and expertise of the Netherlands, the task force aims to develop a national genomics infrastructure of world caliber within five years.
"The agreement with Rosetta and Agilent allows institutions participating in BioASP to access the Rosetta Resolver software at a considerably reduced cost of ownership by leveraging BioASP's server and portal service", said Jan Willem Tellegen, managing director of BioASP. "Researchers will enjoy considerable gains in efficiency because of the highly scalable infrastructure. We are very excited about the opportunity to provide leading researchers throughout the Netherlands access to the Rosetta Resolver system. We expect that cooperation between researchers will be greatly enhanced, because of improved data exchange possibilities and easier access to databases."
"The work being done by BioASP and the government of the Netherlands provides a model for other nations and academic organizations that are uniting together to build genomics research programs," said Barney Saunders, general manager and vice president of Agilent's BioResearch Solutions unit.
As the service is implemented, other tools will be integrated ranging from professional storage services to integration of other gene expression tools, already available through BioASP. New participants are expected to join the microarray services user group in the course of this year, including participants from the private sector.
Rosetta Biosoftware is a provider of enterprise bioinformatics solutions for life science research. Its enterprise software solutions, including the Rosetta Resolver and Rosetta Luminator gene expression data analysis systems, are designed to empower researchers to accelerate discovery with easy-to-use analysis technology. Rosetta Biosoftware is a business unit of Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc..
The Netherlands Bioinformatics Centre (NBIC) is a foundation that aims at stimulating bioinformatics within the genomics sector. NBIC is an integral part of the strategy outlined by the National Genomics Initiative in the Netherlands. It is the responsibility of NBIC to develop an integrated strategy regarding the offering of an innovative service package of bioinformatics tools and applications (BioASP), the development and coordination of an integrated research program (BioRange) and the coordination of education.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
